Cancer

FDA Grants De Novo Authorization for AI-Powered Prostate Cancer Prognostic Software

The risk stratification tool is designed to predict long-term outcomes for patients with non-metastatic prostate cancer.

Cancer

Declining Cancer Screening Rates Prompt Interest in New Detection Methods

A survey indicates a decline in cancer screening rates, contrasted by growing interest in at-home and multi-cancer early detection tests.

Cancer

Bronchoscopic Lung-Biopsy Techniques Have Fewer Complications

New multidisciplinary guidelines bronchoscopic lung biopsy techniques offer tissue sampling adequacy comparable to other testing methods.

HRD Testing Best Practices Issued by AMP

Jun 25, 2025 | Cancer

AMP has published consensus best practice recommendations to standardize HRD testing in clinical laboratories.

Test Predicts Which Patients Will Not Respond to Chemotherapy

Jun 23, 2025 | Cancer

Researchers have developed genomic biomarkers to predict cancer patients’ resistance to chemotherapy, enabling more personalized treatment.

Esophageal Precancer Testing Program Launched at Hoag

Jun 20, 2025 | Unknown Origin & Other Cancer Types

Lucid Diagnostics and Hoag have launched a comprehensive esophageal precancer screening program using the non-endoscopic EsoGuard DNA test.

CAP Updates 23 Cancer Protocols

Jun 19, 2025 | Cancer

CAP has updated 23 cancer protocols to align with the latest standards from AJCC and WHO, enhancing diagnostic precision and patient care.

AI ‘Fragle’ Method Makes Cancer Tracking More Efficient

Jun 18, 2025 | Cancer

Researchers have developed an AI blood test called Fragle to accurately and affordably track cancer treatment response and detect relapse.

Avantect Pancreatic Cancer Test Enters Patient Enrollment Phase

Jun 17, 2025 | Pancreatic

ClearNote Health and University Hospital Southampton have launched the SAFE-D study to evaluate the Avantect Pancreatic Cancer Test.

A Precision Oncology Approach Calls for Regular ESR1 Monitoring

Jun 17, 2025 | Breast

Emerging liquid biopsy techniques enable sensitive, routine monitoring of ESR1 mutations in metastatic HR+ breast cancer.

Quest Diagnostics to Develop MCaST Blood Test

Jun 11, 2025 | Cancer

Quest Diagnostics is partnering with MD Anderson Cancer Center to develop a lab-based blood test for cancer that uses protein biomarkers.

Collaboration Expanded to Accelerate Progress in MASH Diagnosis

Jun 11, 2025 | Unknown Origin & Other Cancer Types

Echosens and Boehringer Ingelheim have expanded their partnership to improve early detection, diagnosis, and care access for MASH.

Liquid Biopsy Launched at Florida Cancer Institute

Jun 11, 2025 | Cancer

Florida Cancer Specialists & Research Institute now offers liquid biopsy, a minimally invasive blood test that enhances cancer diagnosis.

Cancer Screenings Continue Years After Guidelines Change to Limit Unnecessary Tests

Jun 10, 2025 | Cancer

It can take over a decade for unnecessary cancer screenings to significantly decline after updated guidelines advise against them.

Colorectal Cancer Screening: Are Smartphones the Answer?

Jun 5, 2025 | Colorectal

A study found that colorectal cancer screening could be boosted by using a rapid, accurate app-read smartphone FIT.

Gastric Cancer Biomarkers Identified in New Study

Jun 5, 2025 | Unknown Origin & Other Cancer Types

A new research study identifies lncRNAs CBR3-AS1 and PCA3 as significantly overexpressed in gastric cancer tissues.

Partnership to Develop Companion Diagnostic Kit for Lymphoma

Jun 4, 2025 | Lymphoma

Foresight Diagnostics and QIAGEN have entered a global partnership to develop and commercialize a companion diagnostic kit for lymphoma.

Shield MCD Test Gets Breakthrough Device Designation

Jun 4, 2025 | Cancer

Guardant Health’s Shield MCD test has received FDA Breakthrough Device designation for its ability to detect multiple cancer types.

Category: Cancer

Cancer

Cancer

Cancer